Hosted on MSN34m
Eisai wins orphan drug status for Lenvima for esophageal cancer
The U.S. FDA has granted orphan drug designation to Eisai's (OTCPK:ESALF) Lenvima (lenvatinib) for esophageal cancer. The ...
Targeted Oncology50m
Campbell Surveys Participants on Favorable-Risk Frontline Approach in RCC
During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...
MedPage Today2d
Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy
Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...
Targeted Oncology2d
SELECT Trial Outcomes Support Lenvatinib as RAI-Refractory DTC Therapy
During a Case-Based Roundtable® event, Lori J. Wirth, discussed the SELECT trial and the role of multikinase inhibitors in ...
Too Old to Operate3d
Adding Lenvatinib Plus Pembrolizumab to TACE Improves Survival in Intermediate-Stage Hepatocellular Cancer
Lenvatinib plus pembrolizumab has improved survival rates for patients with intermediate-stage hepatocellular cancer, ...
Cure Today5d
FDA Approves MI Cancer Seek as Companion Diagnostic for Adult and Pediatric Patients With Cancer
MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from ...
Pharmac green lights free treatment for some thyroid, liver cancer patients
People with some types of thyroid and liver cancer are getting free access to a targeted treatment for the first time, with ...
NZ Doctor6d
Newly funded medicine to benefit 110 more people with thyroid, liver, and kidney cancer
Pharmac has decided to fund lenvatinib from 1 December 2024 for people with some types of thyroid, liver, and kidney cancer. Lenvatinib (branded as Lenvima) stops the number of cancer cells from ...